CTLA4 and neoplasm: Previous studies using DNMTis to increase the immunogenicity of tumor cells have reported a concomitant increase in the expression of immune checkpoint proteins, such as CTLA-4 and/or PD-L1 on the surface of treated cells, necessitating combination treatment with checkpoint immunotherapy (14, 46).